<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971074</url>
  </required_header>
  <id_info>
    <org_study_id>2009H0156</org_study_id>
    <nct_id>NCT00971074</nct_id>
  </id_info>
  <brief_title>Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy</brief_title>
  <official_title>The Use of Viscosupplementation for the Treatment of Patients With Persistent Non-mechanical Pain Status-post Partial Menisectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grant Jones</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' objective is to analyze a group of patients who have had a partial&#xD;
      meniscectomy but continue to have knee pain after surgery with a double-blind, randomized&#xD;
      prospective study comparing the use of Hylan G-F 20(single injection of a&#xD;
      viscosupplementation) versus placebo injection. The investigators would expect patients who&#xD;
      receive the treatment (Hylan G-F 20) to have lower pain compared to the patients who were in&#xD;
      the placebo group (had the needle injected into the knee but no medication or substance&#xD;
      injected) since Hylan G-F 20 has been shown to decrease pain in arthritic patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A great majority of patients who have a partial menisectomy for mechanical symptoms do well&#xD;
      with full return of function without pain. There is a sub-group of patients who are found to&#xD;
      have Grade II- III chondromalacia lesions (deemed arthritic) at the time of surgery that have&#xD;
      persistent generalized &quot;arthritic-type&quot; pain despite relief of their mechanical symptoms. To&#xD;
      date, there are no published studies analyzing if this treatment is better than no treatment&#xD;
      in this group of patients. We would expect patients who receive the treatment (Hylan G-F 20)&#xD;
      to have lower pain compared to the patients who were in the placebo group (had the needle&#xD;
      injected into the knee but no medication or substance injected) since Hylan G-F 20 has been&#xD;
      shown to decrease pain in arthritic patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Patients did not meet inclusion criteria.&#xD;
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS pain scale</measure>
    <time_frame>0, 2, 6, 12, 18, 26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee injury and Osteoarthritis Outcome Score</measure>
    <time_frame>0, 2, 6, 12, 18, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36Â® Health Survey</measure>
    <time_frame>0, 2, 6, 12, 18, 26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>0, 2, 6, 12, 18, 26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthralgia</condition>
  <arm_group>
    <arm_group_label>Hylan G-F 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single injection of Hylan G-F 20 into the affected knee.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A needle will be inserted through the knee capsule but no medication will be injected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hylan G-F 20</intervention_name>
    <description>6 ml intra-articular injection given once. The injection takes approximately 15 seconds.</description>
    <arm_group_label>Hylan G-F 20</arm_group_label>
    <other_name>Synvisc One</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Injection</intervention_name>
    <description>A needle will be inserted through the knee capsule but no medication will be injected.</description>
    <arm_group_label>Sham Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60&#xD;
&#xD;
          -  S/P partial medial and/or lateral partial meniscectomy&#xD;
&#xD;
          -  Pre-operative MRI diagnosed meniscal tear&#xD;
&#xD;
          -  Diffuse, non-focal arthroscopically diagnosed ICRS Grade II or III chondromalacia.&#xD;
             (used to determine the presence of tibiofemoral osteoarthritis)&#xD;
&#xD;
          -  Baseline VAS pain score between 50 and 80mm.&#xD;
&#xD;
          -  Persistent, generalized knee pain without mechanical symptoms&#xD;
&#xD;
          -  Kellgren/Lawrence (K/L) grade II or III (used to determine the presence of&#xD;
             tibiofemoral osteoarthritis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral arthroscopy (within 6 months pre- and post- initial VAS score.&#xD;
&#xD;
          -  Complete meniscectomy&#xD;
&#xD;
          -  Microfracture (via drilling, picking, abrading, thermal or radiofrequency or any&#xD;
             procedure that violates the subchondral plate)&#xD;
&#xD;
          -  Focal chondral lesion visualized on arthroscopy or any focal cartilage procedure (e.g.&#xD;
             ACI, OATS, mosaicplasty, etc)&#xD;
&#xD;
          -  Concomitant ligamentous injury or repair&#xD;
&#xD;
          -  K/L stage I or IV&#xD;
&#xD;
          -  Significant Varus or Valgus clinical malalignment&#xD;
&#xD;
          -  S/P tibial osteotomy in target knee&#xD;
&#xD;
          -  Isolated patello-femoral OA or isolated anterior knee pain&#xD;
&#xD;
          -  Prosthetic implant in either knee&#xD;
&#xD;
          -  Re-injury in time between original surgery and baseline visit&#xD;
&#xD;
          -  Inflammatory arthritis (e.g. rheumatoid arthritis, gout, pseudogout&#xD;
             (chondrocalcinosis), lupus, etc)&#xD;
&#xD;
          -  Obesity with BMI &gt; 35 (at time of initial VAS score&#xD;
&#xD;
          -  NSAIDs or opiates within one week of baseline randomization or during trial period&#xD;
&#xD;
          -  Known allergy to viscosupplements, known allergy to avian, egg or feather products&#xD;
&#xD;
          -  Prior Viscosupplementation use in ipsilateral knee&#xD;
&#xD;
          -  Oral steroids (within 4 weeks of initial VAS score)&#xD;
&#xD;
          -  IA steroids in target knee within 6 months&#xD;
&#xD;
          -  Significant medical co-morbidities ( e.g. malignancy, hepatic, renal, cardiac,&#xD;
             pulmonary, gastrointestinal disease) in the judgment of the investigator&#xD;
&#xD;
          -  Known hip disease&#xD;
&#xD;
          -  Pregnant or nursing (at time of injection, pregnancy test at visit)&#xD;
&#xD;
          -  Active infection of either lower extremity or past history of septic arthritis&#xD;
&#xD;
          -  Venous or lymphatic stasis in either lower extremity&#xD;
&#xD;
          -  Enrolled in clinical trial within 3 months of baseline&#xD;
&#xD;
          -  Contralateral knee arthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant Jones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University Sports Medicine Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Grant Jones</investigator_full_name>
    <investigator_title>Associate Professor-Clinical, Orthopaedics</investigator_title>
  </responsible_party>
  <keyword>Arthralgia</keyword>
  <keyword>Viscosupplementation</keyword>
  <keyword>Knee</keyword>
  <keyword>Menisci, Tibial</keyword>
  <keyword>Surgery, Outpatient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

